Zhejiang Taimei Medical Technology Co., Ltd. (“TAIMEI TECH”) disclosed a share repurchase conducted on 10 July 2026 under its approved buy-back mandate.

On-market purchase • Date: 10 July 2026 • Volume: 287,200 H shares • Price range: HK$5.50–HK$6.28; volume-weighted average HK$5.98 • Cash outlay: HK$1.72 million

Revised share capital • Issued shares (ex-treasury) fell to 197.75 million from 198.04 million, a 0.15 % reduction. • Treasury stock rose to 2.84 million shares, lifting total issued share count (including treasury) to 200.59 million.

Mandate utilisation and limits • The current repurchase forms part of the mandate approved on 23 June 2026 allowing up to 20.02 million shares to be bought back. • Cumulative purchases since mandate inception total 2.42 million shares, equivalent to 1.21 % of the company’s issued share base at the approval date. • In accordance with Hong Kong listing rules, TAIMEI TECH is restricted from issuing new shares or disposing of treasury shares until 9 August 2026.

Regulatory confirmation The company affirmed that all transactions complied with Hong Kong Stock Exchange Main Board requirements and that no material changes have arisen relative to the explanatory statement released on 1 June 2026.